• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

EQL Pharma

23.70 SEK

-0.21 %

Less than 1K followers

EQL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.21 %
-22.68 %
-57.30 %
-59.00 %
-52.79 %
-72.60 %
-26.85 %
-35.95 %
+340.95 %

EQL Pharma operates in the pharmaceutical industry and focuses on the development, manufacturing and distribution of generic medicines. The company's products are aimed at healthcare institutions and patients who need cost-effective treatment options. The business is global with a primary presence in Europe, North America and Asia. EQL Pharma was founded in 2006 and is headquartered in Lund, Sweden.

Read more
Market cap
699.85M SEK
Turnover
633.06K SEK
Revenue
432.66M
EBIT %
11.25 %
P/E
56.43
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
7.8
2026

Interim report Q1'27

20.8
2026

General meeting '26

5.11
2026

Interim report Q2'27

Press release5/11/2026, 5:16 AM

DNB Carnegie Access: EQL Pharma: Near-term reset; solid execution needed to rebuild the case

EQL Pharma
Press release5/8/2026, 7:17 AM

DNB Carnegie Access: EQL Pharma: Better-than-feared Q4 overshadowed by cautious outlook

EQL Pharma
Regulatory press release5/8/2026, 5:00 AM

Year-end Report April 2025 - March 2026

EQL Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release4/27/2026, 11:12 AM

EQL Pharma in process of recruiting new Chief Supply Chain Officer (CSCO)

EQL Pharma
Press release4/22/2026, 11:01 AM

Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2025/26

EQL Pharma
Press release4/20/2026, 4:58 AM

DNB Carnegie Access: EQL Pharma: Recovery continues, but near-term headwinds – Q4 preview

EQL Pharma
Press release3/27/2026, 3:48 PM

EQL Pharma CEO sells shares to finance capital gains tax from option redemption

EQL Pharma
Press release3/25/2026, 9:36 AM

EQL Pharma: Mellozzan® (melatonin) has been approved in Italy

EQL Pharma
Regulatory press release2/12/2026, 12:22 PM

EQL Pharma: Nomination committee for the 2026 Annual General Meeting

EQL Pharma
Press release2/4/2026, 8:19 AM

DNB Carnegie Access: EQL Pharma: Solid Q3 with branded-driven EBIT beat – worst behind it

EQL Pharma
Press release2/3/2026, 1:25 PM

DNB Carnegie Access: EQL Pharma: Q3 2025/26 initial: Beat driven by strong branded sales

EQL Pharma
Regulatory press release2/3/2026, 1:15 PM

Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026

EQL Pharma
Regulatory press release2/3/2026, 11:30 AM

EQL Pharma: Interim Report April - December 2025

EQL Pharma
Press release1/27/2026, 6:15 AM

DNB Carnegie Access: EQL Pharma: From reset to recovery – Q3 2025/26 preview

EQL Pharma
Press release1/15/2026, 10:40 AM

Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26

EQL Pharma
Regulatory press release1/7/2026, 12:29 PM

Notice of extraordinary general meeting in EQL Pharma AB

EQL Pharma
Regulatory press release12/4/2025, 9:00 AM

EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO)

EQL Pharma
Regulatory press release12/3/2025, 1:36 PM

EQL Pharma recruits Allan Sylvest Aasberg as new Chief Financial Officer (CFO)

EQL Pharma
Regulatory press release11/17/2025, 12:57 PM

EQL Pharma AB (publ) publishes prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm

EQL Pharma
Press release11/14/2025, 12:49 PM

EQL Pharma: Methenamine Hippurate (branded as Cystohipp©) have gained marketing approval in Germany

EQL Pharma